CFDE Data Portal | Search LINC01856

	Label	Description
	LINC01856 Gene (Entity type)	ENSG00000237574 - long intergenic non-protein coding RNA 1856
	GSE239844 crizotinib 7 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE201110 SIRT4 overexpression Capan-2 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 14 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182150 KIT LSD1 MYC inhibition 2 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 11 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 11 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Breast 20-29 vs 40-49 Down Gene Set (Entity type)	A Gene Set from GTEx

LINC01856

ENSG00000237574 - long intergenic non-protein coding RNA 1856

GSE239844 crizotinib 7 v 0 human up

A Gene Set from LINCS

GSE201110 SIRT4 overexpression Capan-2 0 v 1 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 5 human up

A Gene Set from LINCS

GSE239844 crizotinib 4 v 5 human up

A Gene Set from LINCS

GSE233679 nicotinamide 14 v 4 human dn

A Gene Set from LINCS

GSE182150 KIT LSD1 MYC inhibition 2 v 5 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 11 v 6 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 11 v 9 human up

A Gene Set from LINCS

GTEx Breast 20-29 vs 40-49 Down

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.